Generex retained Donohoe to tell them what they ha
Post# of 36566
(Total Views: 243)
Posted On: 10/03/2019 2:38:06 PM
Generex retained Donohoe to tell them what they have done wrong in addition to what they have done right. It is then Generex' job to make the necessary corrections. I don't think this is an easy or smooth process, but the guts of the business plan hinges on the uplisting.
I don't think this daily hand-wringing over the pps is necessary or healthy. Two hours before market close and we've barely traded over 10K shares. GNBT is not on the equity radar. Even the 1:20 dividend didn't generate a great deal of trading, if I remember right.
After all these months we still don't know the exact steps that GNBT will have to take in order to uplist. Didn't it take two failed votes for the R/S to get us knocked of NASDAQ? And that process took place over a period of months. NASDAQ and Donohoe were not paid so that uplisting would fail, but we have to let them do their jobs. Should we close at 1.99 do you really expect MMPJoe to send out a PR that the uplisting has failed and we are doomed to OTC Hades for the rest of the company's existence? I don't think so.
I haven't changed my opinion. There will be no major move upward in the pps during the short term unless there is news of earnings, non-toxic funding, major progress in one of the clinical trials, or partnership. Long term the pps continues to depend on execution of the business plan which is in its infancy.
I don't think this daily hand-wringing over the pps is necessary or healthy. Two hours before market close and we've barely traded over 10K shares. GNBT is not on the equity radar. Even the 1:20 dividend didn't generate a great deal of trading, if I remember right.
After all these months we still don't know the exact steps that GNBT will have to take in order to uplist. Didn't it take two failed votes for the R/S to get us knocked of NASDAQ? And that process took place over a period of months. NASDAQ and Donohoe were not paid so that uplisting would fail, but we have to let them do their jobs. Should we close at 1.99 do you really expect MMPJoe to send out a PR that the uplisting has failed and we are doomed to OTC Hades for the rest of the company's existence? I don't think so.
I haven't changed my opinion. There will be no major move upward in the pps during the short term unless there is news of earnings, non-toxic funding, major progress in one of the clinical trials, or partnership. Long term the pps continues to depend on execution of the business plan which is in its infancy.
(2)
(0)